



**COLORADO**

Department of Health Care  
Policy & Financing

**AGENDA: DUR BOARD MEETING  
Colorado Medicaid DUR  
Department of Health Care Policy and Financing**

Skaggs School of Pharmacy and Pharmaceutical Sciences Building  
12850 East Montview Blvd, Aurora CO 80045  
Seminar Room- Room 1000; First floor  
Parking available in the Henderson/Visitor Parking Garage

November 17, 2015

6:00 p.m. Closed Executive Session for Board Members

7:00 p.m. – 9:00 p.m. Open Session

**DUR BOARD MEMBERS and CO DUR MEMBERS**

LeWayne Garrison, MD  
Karen Weber, DO  
James 'Rick' Kant, RPh  
Pam Reiter, PharmD  
Edra Weiss, MD  
Sheila Botts, PharmD  
Industry Representative (TBD)  
Kerstin Froyd, MD  
Jim Regan, MD

Robert Lodge, PharmD  
Robert L Page, PharmD, MSPH  
(CO DUR)  
Nila Mahyari, PharmD (CO DUR)  
Jon Campbell, PhD (CO DUR)  
Gina Moore, PharmD

**1. Executive Session (Closed)**

- Approval of the minutes from the previous meeting
- Policy Updates: Fish Oil; 300 MED Limit
- Review Retro-DUR reports
- Quarterly Drug Utilization Reports
- FDA updates  
Summary of findings for Metabolic Screening Among Children Taking Antipsychotics

**2. Roll Call**

**3. Approval of the minutes from the August 2015 meeting**

**4. Rules**

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.  
[www.colorado.gov/hcpf](http://www.colorado.gov/hcpf)



- Agenda items must be approved in advance, including requests to present information. Please contact Robert Lodge at (303) 866-3105 if you want to add an agenda item. Visitors are welcome during the open portion of the meeting only.
- Anyone wishing to provide testimony must contact the DUR Coordinator Robert Lodge (Robert.Lodge@state.co.us) at 303-866-3105 or at least 24 hours before the meeting.

## 5. Open Session

### A. Unfinished Business and General Orders

#### Update on the following (Update of criteria implemented October 1, 2015):

- Hepatitis C agents
- Oral anticoagulants
- Bisphosphonates
- Oral biguanides
- Erythropoiesis stimulating agents
- Hypoglycemic combinations
- Meglitinides
- DPP4 inhibitors
- GLP-1 analogues
- Amylin agents
- Thiazolidinediones
- Overactive bladder agents
- Stimulants and other ADHD agents

### B. New Business

#### Proposed Criteria for current PDL:

- Antiemetics
- New Generation Antidepressants
- Anti-Herpetic Agents
- Oral Anti-Platelet
- Oral Fluoroquinolones
- Pancreatic Enzymes
- Proton Pump Inhibitors
- Pulmonary Arterial Hypertension Agents
- Targeted Immune Modulators
- Triptans

#### Proposed Criteria for Other Agents:

- PCSK9 Class-Wide Criteria
- Omega-3 Ethyl Esters Criteria
- Promacta Criteria



- Kalydeco Criteria Update
- Morphine Equivalent Daily Limits discussion

## 6. Adjourn

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at 303- 866-3105 or [robert.lodge@state.co.us](mailto:robert.lodge@state.co.us) or the 504/ADA Coordinator [hcpf504ada@state.co.us](mailto:hcpf504ada@state.co.us) at least one week prior to the meeting to make arrangements.

